Cambridge hybrid closed-loop system in very young children with type 1 diabetes reduces caregivers’ fear of hypoglycemia and improves their well-being.
Year: 2022
Type: other
Abstract: Objective To evaluate the impact of CamAPS FX hybrid closed-loop automated insulin delivery (HCL) in very young children with type 1 diabetes (T1D) on caregivers’ well-being, fear of hypoglycemia and sleepiness. Research Design Multinational, open label, randomized crossover study. Children (1-7years) with T1D received treatment for two 4-month periods in random order, comparing HCL with sensor augmented pump (SAP) (control). At baseline and after each treatment period, caregivers were invited to complete WHO-5, Hypoglycemia Fear Survey (HFS) and Epworth Sleepiness Scale (ESS). Results Caregivers of 74 children (mean±SD: age 5±2 years; 42% female, baseline HbA1c 7.3±0.7%) participated. Results revealed significantly lower scores for hypoglycemia fear (p<.001) and higher for well-being (p<.001) after HCL treatment. A trend towards a reduction in sleepiness score was observed (p=0.09). Conclusion Our results suggest a better well-being and less hypoglycemia fear in caregivers of very young children with T1D on CamAPS FX HCL.
Authors: Carine de Beaufort, Ulrike Schierloh, Ajay Thankamony, Julia Ware, Malgorzata E Wilinska, Elke Fröhlich-Reiterer, Thomas M. Kapellen, Birgit Rami‐Merhar, Sabine E. Hofer, Fiona M. Campbell, James Yong, Laura E. Bocchino, Judy Sibayan, Julia Lawton, Stéphane Roze, Maria Fritsch, Alena Thiele, Janet M Allen, Charlotte Boughton, Julia K. Mader, Craig Kollman, Roman Hovorka, Ineke M. Pit-ten Cate
Institutions: Centre Hospitalier de Luxembourg, University of Cambridge
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4301187608